StemCyte (4178) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 永笙-KY

StemCyte (4178) reported revenue of NT$33 million for Oct 2026, +16.0% year on year and +7.6% from the previous month. Revenue for Jan–Oct 2026 was NT$312.6 million (+4.0% year on year).

Year-on-year revenue growth: 7 months in a row. →

In Oct 2026, it ranked No. 115 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$32.9 million24/10Nov 2024 NT$31.9 millionDec 2024 NT$38.6 millionJan 2025 NT$32.4 millionFeb 2025 NT$33.7 million25/02Mar 2025 NT$38.1 millionApr 2025 NT$25.2 millionMay 2025 NT$28.7 millionJun 2025 NT$32.2 million25/06Jul 2025 NT$28.5 millionAug 2025 NT$29.3 millionSep 2025 NT$24 millionOct 2025 NT$28.5 million25/10Nov 2025 NT$30.9 millionDec 2025 NT$27.4 millionJan 2026 NT$30.9 millionFeb 2026 NT$29.1 million26/02Mar 2026 NT$27.8 millionApr 2026 NT$32.7 millionMay 2026 NT$30.2 millionJun 2026 NT$33.8 million26/06Jul 2026 NT$32.4 millionAug 2026 NT$32 millionSep 2026 NT$30.7 millionOct 2026 NT$33 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$33 million+16.0%+7.6%
Sep 2026NT$30.7 million+28.2%-3.9%
Aug 2026NT$32 million+9.0%-1.4%
Jul 2026NT$32.4 million+13.7%-4.1%
Jun 2026NT$33.8 million+4.9%+12.0%
May 2026NT$30.2 million+5.0%-7.7%
Apr 2026NT$32.7 million+29.7%+17.6%
Mar 2026NT$27.8 million-27.1%-4.5%
Feb 2026NT$29.1 million-13.6%-6.0%
Jan 2026NT$30.9 million-4.5%+13.1%
Dec 2025NT$27.4 million-29.1%-11.4%
Nov 2025NT$30.9 million-3.3%+8.4%
Oct 2025NT$28.5 million-13.3%+18.9%
Sep 2025NT$24 million-24.6%-18.3%
Aug 2025NT$29.3 million-5.4%+2.8%
Jul 2025NT$28.5 million-18.8%-11.5%
Jun 2025NT$32.2 million+17.6%+12.2%
May 2025NT$28.7 million-6.6%+14.1%
Apr 2025NT$25.2 million-29.0%-33.9%
Mar 2025NT$38.1 million+33.6%+13.2%
Feb 2025NT$33.7 million+9.0%+3.9%
Jan 2025NT$32.4 million+14.4%-16.1%
Dec 2024NT$38.6 million+28.2%+20.9%
Nov 2024NT$31.9 million+12.5%-2.8%
Oct 2024NT$32.9 million—+3.4%

Jan–Oct 2026 cumulative: NT$312.6 million (+4.0% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: StemCyte vs PEC / StemCyte vs Lotus Pharm / StemCyte vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16